Trial · NCT01516879
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change From Baseline in LDL-C at Week 52 | Baseline and Week 52 | Full Analysis Set (all randomized subjects who received at least 1 dose of study drug). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in LDL-C at Week 52 | Baseline and Week 52 | Full Analysis Set | mg/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants With an LDL-C Response at Week 52 | Week 52 | Full Analysis Set | percentage of participants | NUMBER |
| SECONDARY | Percent Change From Baseline in LDL-C at Week 12 | Baseline and Week 12 | Full Analysis set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Total Cholesterol at Week 12 | Baseline and Week 12 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Total Cholesterol at Week 52 | Baseline and Week 52 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52 | Baseline and Week 52 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Apolipoprotein B at Week 52 | Baseline and Week 52 | Full analysis set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52 | Baseline and Week 52 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52 | Baseline and Week 52 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Lipoprotein(a) at Week 52 | Baseline and Week 52 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Triglycerides at Week 52 | Baseline and Week 52 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52 | Baseline and Week 52 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52 | Baseline and Week 52 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Week 12 to Week 52 in LDL-C | Week 12 and Week 52 | The Effect Durability Analysis Set included participants in the FAS who adhered to the scheduled study drug and had nonmissing LDL-C values at Baseline, Week 12 and Week 52. | percent change | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01516879/outcomes